Intravenous versus subcutaneous route pharmacokinetics of paracetamol (acetaminophen) in palliative care patients: study protocol for a randomized trial (ParaSCIVPallia)

Marine Vernant, Marie Lepoupet, Christian Creveuil, Antoine Alix, Charlotte Gourio, Laure Peyro-Saint-Paul, Veronique Lelong-Boulouard, Cyril Guillaumé, Marine Vernant, Marie Lepoupet, Christian Creveuil, Antoine Alix, Charlotte Gourio, Laure Peyro-Saint-Paul, Veronique Lelong-Boulouard, Cyril Guillaumé

Abstract

Background: Among palliative care (PC) patients who are administered paracetamol, the subcutaneous (SC) route is often an alternative to the intravenous (IV) route. Yet pharmacological and clinical data on whether these are equivalent pharmacokinetically are lacking. Many French palliative teams are now empirically using paracetamol by the SC route, but there are no data to support this practice. This trial aims to compare the pharmacokinetic (PK) parameters of paracetomol between the IV and SC routes in PC patients.

Methods/design: This is a randomized, open, crossover study in two PC centers. The primary endpoints are AUC0-t, AUC0-∞, Cmax, Vd, and t1/2. All adverse events will be reported for a safety analysis. Twenty adult PC patients with an IV device having spontaneous pain not related to care, with a numeric pain rate scale > 3/10, or having a systematic prescription of paracetamol as the usual treatment will be included. All patients also have to meet all eligibility criteria.

Conclusion: This is the first study comparing PK parameters for IV paracetamol versus SC paracetamol in PC patients.

Trial registration: ClinicalTrials.gov, NCT03944044. Registered on 4 June 2019. Committee for the protection of persons (CPP) 18.09.05.58206 approval 4 October 2018. National Drug Safety Agency (ANSM; Agence Nationale de Sécurité Médicament) MEDAECNAT-2018-09-00009 approval 29 November 2018.

Keywords: Acetaminophen; Intravenous route; Palliative care; Paracetamol; Pharmacokinetics; Subcutaneous route.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Protocol design
Fig. 2
Fig. 2
Protocol steps and intervention: SPIRIT figure

References

    1. Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca AF, et al. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Palliat Med. 2005;19:208–219. doi: 10.1191/0269216304pm1006oa.
    1. Bruera E, Legris MA, Kuehn N, et al. Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. J Pain Symptom Manag. 1990;5:218–220. doi: 10.1016/0885-3924(90)90014-B.
    1. Leheup BF, Ducousso S, Picard S, et al. Subcutaneous administration of paracetamol-good local tolerability in palliative care patients: an observational study. Palliat Med. 2018;32:1216–1221. doi: 10.1177/0269216318772472.
    1. Guzman NA, Molina DR, Nunez BF, et al. Bioequivalence and pharmacokinetic evaluation study of acetaminophen vs. acetaminophen plus caffeine tablets in healthy mexican volunteers. Drugs R D. 2016;16:339–345. doi: 10.1007/s40268-016-0145-9.
    1. Bartz L, Klein C, Seifert A, et al. Subcutaneous administration of drugs in palliative care: results of a systematic observational study. J Pain Symptom Manag. 2014;48:540–547. doi: 10.1016/j.jpainsymman.2013.10.018.
    1. Yi S, Chung YJ, Kim TE, et al. Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. Clin Ther. 2011;33:728–737. doi: 10.1016/j.clinthera.2011.04.023.
    1. Palma-Aguirre JA, Villalpando-Hernandez J, Novoa-Heckel G, et al. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Clin Ther. 2009;31:399–410. doi: 10.1016/j.clinthera.2009.02.002.
    1. O'Neal JB, Freiberg AA, Yelle MD, et al. Intravenous vs oral acetaminophen as an adjunct to multimodal analgesia after total knee arthroplasty: a prospective, randomized, double-blind clinical trial. J Arthroplast. 2017;32:3029–3033. doi: 10.1016/j.arth.2017.05.019.
    1. Oosten AW, Abrantes JA, Jonsson S, et al. A prospective population pharmacokinetic study on morphine metabolism in cancer patients. Clin Pharmacokinet. 2017;56:733–746. doi: 10.1007/s40262-016-0471-7.
    1. Allegaert K, Olkkola KT, Owens KH, et al. Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol. 2014;14:77. doi: 10.1186/1471-2253-14-77.
    1. Lynch PM, Butler J, Huerta D, et al. A pharmacokinetic and tolerability evaluation of two continuous subcutaneous infusion systems compared to an oral controlled-release morphine. J Pain Symptom Manag. 2000;19:348–356. doi: 10.1016/S0885-3924(00)00130-5.
    1. Kawade RM, Burade KB, Ghiware NB, et al. Evaluation of bioequivalence and pharmacokinetic studies of two formulation of paracetamol ER 650 mg in healthy adult volunteers. World J Pharm Pharm Sci. 2013;2:5449–5458.
    1. EMEA . Guideline on the investigation of bioequivalence, CPMP/EWP/QWP/1401/98 Rev. London: European Medical Agency; 2010.
    1. Kraychete DC, Sakata RK. Use and rotation of opioids in chronic non-oncologic pain. Rev Bras Anestesiol. 2012;62:554–562. doi: 10.1016/S0034-7094(12)70155-1.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する